Provided by Tiger Trade Technology Pte. Ltd.

Avalo Therapeutics Inc

14.95
-0.3800-2.48%
Pre-market: 15.270.3200+2.14%08:34 EDT
Volume:932.39K
Turnover:13.99M
Market Cap:801.77M
PE:-3.39
High:15.57
Open:15.24
Low:14.78
Close:15.33
52wk High:24.27
52wk Low:12.41
Shares:53.63M
Float Shares:40.15M
Volume Ratio:0.68
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4100
EPS(LYR):-5.8400
ROE:-36.27%
ROA:-18.50%
PB:1.79
PE(LYR):-2.56

Loading ...

Avalo Therapeutics Grants New-Employee Stock Options for 101,600 Shares at $15.47 Each

Reuters
·
Sep 30

Avalo Therapeutics Announces Inducement Grants to New Employees Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 30

Avalo Therapeutics to Present Phase 2 LOTUS Trial Results for Abdakibart in Hidradenitis Suppurativa at EADV 2026

Reuters
·
Sep 23

Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 12,394 Common Shares for $202,436.79

Reuters
·
Sep 19

Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of 10,185 Common Shares Worth $179,485.72

Reuters
·
Sep 12

Avalo Therapeutics Grants 78,000 Inducement Stock Options Priced at $19.34 Per Share

Reuters
·
Sep 05

Avalo Therapeutics CMO Mittie Doyle Sells 679 Common Shares for $13,580

Reuters
·
Sep 02

Avalo Therapeutics CFO Christopher Ryan Sullivan Disposes of Common Shares Worth $1.44 Million

Reuters
·
Aug 20

Is Avalo Therapeutics (AVTX) Cheap As Wider Q2 Losses Meet A Lower P B?

Simply Wall St.
·
Aug 19

Avalo Therapeutics CMO Mittie Doyle Disposes of 679 Common Shares Worth $13,580

Reuters
·
Aug 13

Avalo Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

CG Oncology Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 06

Avalo Q2 2026 Earnings: $472.2 Million Supports 2027 Clinical Milestones

TradingKey
·
Aug 06

Avalo Therapeutics Posts Corporate Deck Spotlighting IL-1β Inhibitor Pipeline for Hidradenitis Suppurativa

Reuters
·
Aug 06

Avalo Q2 FY26 Net Loss Widens to $36.4 Million; R&D Expense Rises 66.1% to $23.4 Million

Reuters
·
Aug 06

Press Release: Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Dow Jones
·
Aug 06

Avalo Therapeutics Inc Expected to Post a Loss of 58 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Avalo Therapeutics CMO Mittie Doyle Disposes of Common Shares Worth $20,000

Reuters
·
Jul 30

Avalo Therapeutics - Selling Stockholders May Sell up to 128,189 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jul 29

Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares

MT Newswires Live
·
Jul 18